NZ512289A - Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases - Google Patents

Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Info

Publication number
NZ512289A
NZ512289A NZ512289A NZ51228900A NZ512289A NZ 512289 A NZ512289 A NZ 512289A NZ 512289 A NZ512289 A NZ 512289A NZ 51228900 A NZ51228900 A NZ 51228900A NZ 512289 A NZ512289 A NZ 512289A
Authority
NZ
New Zealand
Prior art keywords
treatment
neurodegenerative diseases
heterocyclic compounds
fused heterocyclic
compounds
Prior art date
Application number
NZ512289A
Other languages
English (en)
Inventor
Mette Gronborg
Arne Moller
Dan Peters
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NZ512289A publication Critical patent/NZ512289A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ512289A 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases NZ512289A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900061 1999-01-19
PCT/DK2000/000012 WO2000043397A1 (en) 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NZ512289A true NZ512289A (en) 2003-06-30

Family

ID=8089290

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512289A NZ512289A (en) 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Country Status (10)

Country Link
US (1) US6576641B2 (https=)
EP (1) EP1147113B1 (https=)
JP (1) JP2002535334A (https=)
CN (1) CN1147490C (https=)
AT (1) ATE328887T1 (https=)
AU (1) AU776276B2 (https=)
CA (1) CA2353903A1 (https=)
DE (1) DE60028538T2 (https=)
NZ (1) NZ512289A (https=)
WO (1) WO2000043397A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002249A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395028A2 (fr) * 1977-06-22 1979-01-19 Centre Etd Ind Pharma Derives pyridiniques, leur preparation et leurs application therapeutique
FR2566775B1 (fr) 1984-06-27 1986-10-31 Synthelabo Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
FR2635977B1 (fr) * 1988-09-07 1992-05-15 Synthelabo Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l'obesite
GB8921465D0 (en) * 1989-09-22 1989-11-08 Fujisawa Pharmaceutical Co Bicyclic amine compound and a process for the preparation thereof
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
EP0785939A1 (en) * 1994-10-11 1997-07-30 Takeda Chemical Industries, Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
DK1288203T3 (da) * 1995-09-11 2005-07-11 Aventis Pharma Inc Cykliske nitroner og farmaceutiske præparater, der indeholder dem

Also Published As

Publication number Publication date
CN1147490C (zh) 2004-04-28
DE60028538D1 (de) 2006-07-20
US20020013336A1 (en) 2002-01-31
WO2000043397A1 (en) 2000-07-27
JP2002535334A (ja) 2002-10-22
AU3033300A (en) 2000-08-07
ATE328887T1 (de) 2006-06-15
DE60028538T2 (de) 2007-06-21
CN1336929A (zh) 2002-02-20
US6576641B2 (en) 2003-06-10
AU776276B2 (en) 2004-09-02
EP1147113A1 (en) 2001-10-24
CA2353903A1 (en) 2000-07-27
EP1147113B1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
GB0005251D0 (en) Therapeutic compounds
PL355912A1 (en) Novel compounds
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
GB0025173D0 (en) Therapeutic agents
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
NO990433D0 (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
MY103352A (en) Piperazinyl-heterocyclic compounds
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
EP0204597A3 (en) Use of alfuzosine in the treatment of urinary affections
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
NZ513096A (en) Compositions for treating inflammatory response
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
UA41355C2 (uk) Засіб для лікування нейро-сніду
NZ512289A (en) Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
IL150125A0 (en) Novel compounds
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed